Japanese Firm Selects iCardiac for Oncology Trial

Article

iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company.

iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company. This study will utilize iCardiac’s Rapid QT service offering, which assists trial sites in making accurate patient inclusion/exclusion decisions.

Read the full release here

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.